Oxfordshire, UK, 27 April 2020 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2507 Phase I study at the American Association for Cancer Research (AACR) Annual Meeting 2020. The Phase I clinical trial, conducted at The University of Texas MD […]
Oxfordshire, UK, 4 December 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of […]
ANNOUNCEMENT Oxfordshire, UK, 17 September 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced that Dr Stephen Shuttleworth will become Chairman of its Scientific Advisory Board with immediate effect. After almost 12 years with Karus, the Company’s Founding Scientist and CSO (and latterly joint COO/CSO) and Executive […]
Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer (CMO) with immediate effect. Dr McElwaine-Johnn is a Physician with over 25 years’ experience in drug development, most recently as CMO at cancer gene […]
Tim Edwards appointed as Executive Chairman KA2237 and KA2507 – innovative, molecular-targeted anti-cancer therapeutics – progressing in Phase I clinical trials for the treatment of cancer, with clinical responses confirmed for KA2237 in patients with refractory B-cell lymphomas Research and development activities on a novel, differentiated HDAC6 inhibitor series progressing well, with preclinical development candidate […]
Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second […]
Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its COO/CSO will be delivering two presentations at the CHI DoT 11th Annual Kinase Inhibitor Discovery conference, Boston, 27 and 28 September 2017. The presentation on Wednesday 27 September by Stephen […]
Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017. Stephen Shuttleworth, COO & […]
Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a presentation at the 22nd BIO-Europe, Cologne, Germany, 7-9 November 2016. Dr Simon Kerry, Karus’s CEO, will be presenting on the Oncology track, taking place in the […]
First cohort of cancer patients has been dosed with Karus’s lead candidate, KA2237 Potential first-in-class dual-PI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors KA2237 combines an immunotherapeutic response and a direct effect on tumor growth Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active […]
© Karus Therapeutics. All rights reserved
Registered in England & Wales No 05490954
VAT No 871 4126 33
Created by Instinctif Partners
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy